[PDF][PDF] Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non–small-cell lung cancer
C Butts, N Murray, A Maksymiuk, G Goss… - Journal of Clinical …, 2005 - academia.edu
Journal of Clinical Oncology, 2005•academia.edu
Purpose To evaluate the effect of BLP25 liposome vaccine (L-BLP25) on survival and
toxicity in patients with stage IIIB and IV non–small-cell lung cancer (NSCLC). Secondary
objectives included health-related quality of life (QOL) and immune responses elicited by L-
BLP25.
toxicity in patients with stage IIIB and IV non–small-cell lung cancer (NSCLC). Secondary
objectives included health-related quality of life (QOL) and immune responses elicited by L-
BLP25.
Purpose
To evaluate the effect of BLP25 liposome vaccine (L-BLP25) on survival and toxicity in patients with stage IIIB and IV non–small-cell lung cancer (NSCLC). Secondary objectives included health-related quality of life (QOL) and immune responses elicited by L-BLP25.
academia.edu